This website is for the U.S, for the other countries please refer to this link.
SUDOSCAN COMBINED TO OTHER DIAGNOSIS TESTS TO CONFIRM SMALL FIBER NEUROPATHY V. Fabry, A. Gerdelat, B. Acket, P. Cintas, V. Rousseau, E. Uro-Coste, S.
THE UTILITY OF SUDOSCAN TO DIAGNOSE DIABETIC CARDIOVASCULAR AUTONOMIC NEUROPATHY AND DIABETIC POLYNEUROPATHY C. D’amato, C. Greco, G. Lombardo, V. Frattina, M. Campo, C.M.A. Cefalo,
THE BENEFITS OF SUDOSCAN IN EARLY DIAGNOSIS OF DIABETIC PERIPHERAL NEUROPATHY REVIEWED IN THE LANCET Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR,
LONGITUDINAL FOLLOW-UP: SUDOSCAN DEMONSTRATED EFFICACY IN RESULTS FOLLOW-UP SUDOSCAN has proven its clinical utility in the follow-up of sudomotor function. In a Finnish study, SUDOSCAN
SUDOSCAN in Oncology : Chemotherapy InduCed Polyneuropathy Two studies evaluating SUDOSCAN Severe drug-induced neurotoxic adverse effects constitute the second most common cause of dose limitation
Los Angeles, CA – February 14, 2017 — Impeto Medical CEO and Founder Philippe Brunswick is featured on the award-winning, global TV show, Worldwide Business
Promotional Communication. The medical devices SUDOSCAN is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 2021/01/12
